Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Withdrawn Not applicable Interventional

Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer

NCT02250378
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
Radiation · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2015 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

NCT05386550
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, IMRT, Placebo
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Stage III Colon Cancer

NCT00003835
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Stage III Colon Cancer
Interventions
leucovorin calcium, fluorouracil, irinotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Not applicable Interventional

Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer

NCT02040493
View directory record Official record
Conditions
Breast Cancer
Interventions
Intra-operative radiation therapy (IORT)
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Casa Grande, Arizona • Long Beach, California • Pleasant Hill, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 1 Interventional

Phase 1a Study to Evaluate Immunogenicity of ASV®

NCT03673020
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
ASV® AGEN2017 + QS-21 Stimulon® adjuvant
Biological
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 24, 2026, 2:23 AM EDT
Not yet recruiting Phase 3 Interventional

Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

NCT07723469
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
BCS + SRG-514, BCS
Drug · Procedure
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02559024
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
MEDI6469
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 24, 2026, 2:23 AM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

NCT00030563
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, adjuvant therapy, conventional surgery, radiofrequency ablation
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 24, 2026, 2:23 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early Stage
Interventions
TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:23 AM EDT
Not listed Not applicable Interventional

Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis

NCT01892839
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
low dialysate flow, smaller dialyzer, high dialysate flow, larger dialyzer
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Redwood City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Not applicable Interventional

Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery

NCT00470353
View directory record Official record
Conditions
Colorectal Cancer
Interventions
calcium carbonate, cholecalciferol, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Dietary Supplement · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

NCT02450331
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
41
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 24, 2026, 2:23 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

NCT06664151
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions
Fluzone Trivalent
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 24, 2026, 2:23 AM EDT
Not listed Phase 1 Interventional

Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)

NCT02210494
View directory record Official record
Conditions
EMR Ulcer
Interventions
Secretrol
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional

Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors

NCT01148966
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Interventions
aminolevulinic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

NCT04385368
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 1 Interventional

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

NCT02225405
View directory record Official record
Conditions
Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Cisplatin, Docetaxel, Laboratory Biomarker Analysis, Nintedanib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer

NCT01553019
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Proton radiation, Gemcitabine
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Jacksonville, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 3 Interventional Results available

Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00107172
View directory record Official record
Conditions
Lung Cancer
Interventions
surgery, brachytherapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
37
States / cities
Scottsdale, Arizona • Sacramento, California • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 24, 2026, 2:23 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

NCT00796445
View directory record Official record
Conditions
Melanoma
Interventions
GSK 2132231A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
74
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 2 Interventional

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

NCT06774625
View directory record Official record
Conditions
Acute Pain, Postoperative
Interventions
LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine
Drug · Other
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Early Phase 1 Interventional

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

NCT02534376
View directory record Official record
Conditions
Prostate Cancer
Interventions
ezetimibe 10mg-simvastatin 40mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 24, 2026, 2:23 AM EDT
Completed Phase 3 Interventional

Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer

NCT00002852
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions
paclitaxel, carboplatin, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 24, 2026, 2:23 AM EDT